IMPORTANCE: Large-scale whole-exome sequencing studies of head and neck squamous cell carcinoma (HNSCC) have established that the disease is dominated by frequent mutations in tumor suppressor genes with rare activating mutations in oncogenes that would be easily targetable with molecular agents. There was evidence in these reports, however, that activating mutations in phosphoinositide 3-kinase catalytic subunit p110α (PIK3CA) were common in patients with human papillomavirus (HPV)-positive tumors. We set out to test this prediction in oropharyngeal patient samples from our institution. OBJECTIVE: To confirm whether activating mutations in PIK3CA are frequent in HPV-positive HNSCC because this mutated oncogene represents a potential therapeutic target. DESIGN, SETTING, AND PARTICIPANTS: A retrospective search of the London Health Sciences Centre pathology database was performed to identify oropharyngeal cancer samples. DNA from pretreatment primary site biopsy samples from 87 patients were tested for high-risk HPV types 16 and 18 by real-time polymerase chain reaction. MAIN OUTCOMES AND MEASURES: Samples were tested for activating mutations at the 3 mutational hot spots (codons 542, 545, and 1047) by polymerase chain reaction followed by Sanger sequencing using forward and reverse primers. RESULTS: Only 4 of 41 HPV-negative tumors (10%) demonstrated PIK3CA hot spot mutations, including 3 at codon 1047 and 1 at codon 542. Of 46 HPV-positive tumors, 13 (28%) demonstrated activating PIK3CA mutations, including 7 at codon 542, 5 at codon 545, and 1 at codon 1047. The difference in PIK3CA mutation frequency was significantly different between HPV-positive and HPV-negative cancers (P = .03). CONCLUSIONS AND RELEVANCE: Although there has been a suggestion that activating PIK3CA mutations are common in HPV-positive HNSCC, to our knowledge, this is the first study to clearly identify this phenomenon. Targeting PIK3CA with molecular agents in HPV-positive patients may be a mechanism to improve cure rates and decrease treatment toxic effects in this rapidly growing cohort of patients.
IMPORTANCE: Large-scale whole-exome sequencing studies of head and neck squamous cell carcinoma (HNSCC) have established that the disease is dominated by frequent mutations in tumor suppressor genes with rare activating mutations in oncogenes that would be easily targetable with molecular agents. There was evidence in these reports, however, that activating mutations in phosphoinositide 3-kinase catalytic subunit p110α (PIK3CA) were common in patients with human papillomavirus (HPV)-positive tumors. We set out to test this prediction in oropharyngeal patient samples from our institution. OBJECTIVE: To confirm whether activating mutations in PIK3CA are frequent in HPV-positive HNSCC because this mutated oncogene represents a potential therapeutic target. DESIGN, SETTING, AND PARTICIPANTS: A retrospective search of the London Health Sciences Centre pathology database was performed to identify oropharyngeal cancer samples. DNA from pretreatment primary site biopsy samples from 87 patients were tested for high-risk HPV types 16 and 18 by real-time polymerase chain reaction. MAIN OUTCOMES AND MEASURES: Samples were tested for activating mutations at the 3 mutational hot spots (codons 542, 545, and 1047) by polymerase chain reaction followed by Sanger sequencing using forward and reverse primers. RESULTS: Only 4 of 41 HPV-negative tumors (10%) demonstrated PIK3CA hot spot mutations, including 3 at codon 1047 and 1 at codon 542. Of 46 HPV-positive tumors, 13 (28%) demonstrated activating PIK3CA mutations, including 7 at codon 542, 5 at codon 545, and 1 at codon 1047. The difference in PIK3CA mutation frequency was significantly different between HPV-positive and HPV-negative cancers (P = .03). CONCLUSIONS AND RELEVANCE: Although there has been a suggestion that activating PIK3CA mutations are common in HPV-positive HNSCC, to our knowledge, this is the first study to clearly identify this phenomenon. Targeting PIK3CA with molecular agents in HPV-positive patients may be a mechanism to improve cure rates and decrease treatment toxic effects in this rapidly growing cohort of patients.
Authors: Julie A Theurer; William Stecho; John Yoo; Keith Kwan; Bret Wehrli; Vimla Harry; Morgan Black; Nicole Pinto; Eric Winquist; David Palma; Suzanne Richter; John W Barrett; S Danielle MacNeil; Kevin Fung; Christopher J Howlett; Anthony C Nichols Journal: Pathol Oncol Res Date: 2015-08-14 Impact factor: 3.201
Authors: Nabil F Saba; Malania Wilson; Gregory Doho; Juliana DaSilva; R Benjamin Isett; Scott Newman; Zhuo Georgia Chen; Kelly Magliocca; Michael R Rossi Journal: Head Neck Pathol Date: 2014-09-19
Authors: Michelle J Lee; Nan Jin; Jennifer R Grandis; Daniel E Johnson Journal: Biochim Biophys Acta Mol Cell Res Date: 2020-02-19 Impact factor: 4.739
Authors: Darío García-Carracedo; Yi Cai; Wanglong Qiu; Kiyoshi Saeki; Richard A Friedman; Andrew Lee; Yinglu Li; Elizabeth M Goldberg; Elias E Stratikopoulos; Ramon Parsons; Chao Lu; Argiris Efstratiadis; Elizabeth M Philipone; Angela J Yoon; Gloria H Su Journal: Mol Cancer Res Date: 2020-03-09 Impact factor: 5.852
Authors: Michael Frumovitz; Jennifer K Burzawa; Lauren A Byers; Yasmin A Lyons; Preetha Ramalingam; Robert L Coleman; Jubilee Brown Journal: Gynecol Oncol Date: 2016-04-15 Impact factor: 5.482
Authors: Tao Wei; Suyong Choi; Darya Buehler; Denis Lee; Ella Ward-Shaw; Richard A Anderson; Paul F Lambert Journal: Cancers (Basel) Date: 2021-05-10 Impact factor: 6.575